Reclassification of marijuana opens doors for much-needed medical research … – The Conversation
The DEA's proposed reclassification of cannabis from Schedule I to Schedule III represents a watershed moment for medical research opportunities in cannabis medicine. This regulatory shift will remove decades-old barriers to rigorous clinical studies…
Trinity County bans industrial hemp to protect licensed cannabis growers – MMJDaily
Trinity County's decision to ban industrial hemp to protect licensed cannabis operations demonstrates how hemp ban affects medical cannabis patient access. This regulatory approach aims to prevent cross-pollination that could reduce therapeutic cannabis…
Mounjaro Counterfeit Seizure: GLP-1 Clinical Supply Chain Risks
GLP-1 Clinical Relevance #41Contextual Information Background context; limited direct clinical applicability. ⚕ GLP-1 News | CED Clinic NewsSupply Chain InvestigationType 2 DiabetesTirzepatideRegulatory AffairsGlobal Patient PopulationDrug…
Characterizing public comments via Regulations.gov in response to proposed cannabis rescheduling in the United States.
The United States Drug Enforcement Administration's (DEA) proposed rescheduling of cannabis from Schedule I to Schedule III under the Controlled Substances A...
Potential Trump Psychedelic Order Could Reshape Cannabis Industry – MMJDaily
Emerging cannabis industry regulatory changes are influenced by evolving psychedelic policies. These changes could reshape clinical practice frameworks and federal law. Clinicians should stay informed about cannabis industry regulatory changes to adapt…
Bring It On: Meet the Cannabis CMO Welcoming Scrutiny With Open Arms
The cannabis clinical scrutiny embraced by industry leaders marks a pivotal shift toward transparency and patient safety. This approach ensures clinicians have reliable data for evidence-based prescribing decisions. Cannabis clinical scrutiny benefits…
Impact of Medicinal Cannabis Crackdowns on Sales and Patient Access
Medicinal cannabis crackdowns have led to notable declines in sales, reflecting access barriers and regulatory challenges. Understanding these market dynamics is essential for clinicians to anticipate patient care impacts. This analysis of medicinal…
Hemp Businesses in Massachusetts Face Uncertain Future Amid Federal Ban
Federal hemp regulatory uncertainty is creating challenges for Massachusetts hemp businesses and patient access to cannabinoid therapies. The looming federal ban on intoxicating hemp compounds complicates clinical prescribing and treatment continuity.…
Regulating Payment of Participant Data in Clinical Trials | The Regulatory Review
Regulating payment participant data clinical trials is crucial for ensuring ethical standards and scientific integrity. This article discusses how payment structures impact cannabis clinical trials. Understanding these regulations helps improve…
Editorial: Weed Tax Confusion is Budget ‘Deadline’ Hangover – Crain’s Detroit Business
Cannabis wholesale tax policy changes affect patient access to medical cannabis, especially for those needing consistent dosing. Regulatory confusion around cannabis taxation disrupts market pricing and availability. Understanding these policies helps…